• +91-44-24993989

  • info@cpcdiagnostics.in

Blog Lockdown Diaries Enquire Now

Fully automated high throughput diagnostics for COVID-19




YHLO has introduced an effective automated CLIA testing for 2019-nCoV IgG/IgM.

CPC is the first company to launch the automated CLIA platform iFlash 1800 in INDIA, facilitating the fastest screening for COVID -19.

YHLO’s new 2019-nCoV IgG/IgM CLIA assays has the following advantages:

  •   Fast reporting : 27 min
  •   Ease of sample collection : Serum or EDTA plasma
  •   Automated Assay : CLIA platform- 180 test/hr & 300 tests /hr
  •   Test Pack : 2 x 50 tests with builtin calibrators
  •   On board Stability : 28 days after opening
  •   Calibration stability : 28 days
 

  First CLIA Assays

It is the first company to develop a CLIA platform for 2019-nCoV IgG and IgM antibodies which can satisfy the clinical needs to detect antibodies for new 2019-nCoV and offer differential diagnosis to doctors.

  Fast Speed

iFlash 1800 offers comprehensive CLIA solutions up to 180 T/H for detecting 2019-nCoV . Fastest reporting in 27 min.

  Stable Raw Materials

With a strong R&D team in protein engineering and immunoassay, YHLO achieves stable supply of the raw materials for these CLIA assays.

  Strong Anti-Interference Ability

YHLO has made initial evaluation of these assays, and results showed that these assays have strong anti-interference ability to other respiratory pathogens (e.g. legionella Pneumophila, Mycoplasma Pneumonia, Chlamydia Pneumonia, Q Fever from Rickettsia, Adenovirus, RSV-Respiratory Syncytial Virus, Influenza A, Influenza B, Parainfluenza 1, 2, 3, etc.).

For more information please visit the website of YHLO with the below url:

  Performance of SARS-CoV-2 IgM/IgG Kits in Thailand

  Contribution to Wuhan with SARS-CoV-2 IgG/IgM Assays